Showing 3,861 - 3,880 results of 21,342 for search '(( significant decrease decrease ) OR ( significant ((event decrease) OR (point decrease)) ))', query time: 0.72s Refine Results
  1. 3861
  2. 3862

    S2 Fig - by Aihong Zheng (20571034)

    Published 2025
    Subjects:
  3. 3863
  4. 3864
  5. 3865

    Differences in mean scores of upper extremity performance in all five accelerometer-derived variables across four time points- pre-HABIT, post-HABIT, 3-month, and 6-month post-HABI... by Shailesh S. Gardas (20490020)

    Published 2024
    “…The trends seen in the line graphs above indicate a decrease in all the accelerometer derived variables at 3-month time point (except use ratio) suggesting decrease in bimanual performance. …”
  6. 3866
  7. 3867
  8. 3868
  9. 3869
  10. 3870
  11. 3871
  12. 3872
  13. 3873
  14. 3874

    Effects of ABZ on the viability of <i>M. corti.</i> by Inés Guarnaschelli (18102211)

    Published 2025
    “…Viability was not significantly affected for at least 3 days, and then decreased to 38% and 10% for ABZ 1 µM and 10 µM, respectively, by day 10. …”
  15. 3875
  16. 3876

    Table1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
  17. 3877

    Image2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
  18. 3878

    Table2_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.docx by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
  19. 3879

    Image1_Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.TIF by Qiong Jie (13270095)

    Published 2024
    “…The risk of AEs such as decreased platelet count, anemia, decreased white blood cell count, pneumonitis, asthenia, and edema caused by pralsetinib is significantly higher than that of selpercatinib. …”
  20. 3880

    Minimal data set. by Xiaoxia Liu (294088)

    Published 2024
    “…In contrast, with a negative Soret coefficient, the growth rate of the spherical crystals increases as the coefficient decreases, and the solute concentration near the interface decreases. …”